RU2017135539A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017135539A3 RU2017135539A3 RU2017135539A RU2017135539A RU2017135539A3 RU 2017135539 A3 RU2017135539 A3 RU 2017135539A3 RU 2017135539 A RU2017135539 A RU 2017135539A RU 2017135539 A RU2017135539 A RU 2017135539A RU 2017135539 A3 RU2017135539 A3 RU 2017135539A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15167927 | 2015-05-18 | ||
EP15167927.1 | 2015-05-18 | ||
EP16150508 | 2016-01-08 | ||
EP16150508.6 | 2016-01-08 | ||
PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021119777A Division RU2021119777A (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017135539A RU2017135539A (ru) | 2019-06-18 |
RU2017135539A3 true RU2017135539A3 (ja) | 2019-11-29 |
RU2754466C2 RU2754466C2 (ru) | 2021-09-02 |
Family
ID=56134305
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017135539A RU2754466C2 (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид с противораковой активностью |
RU2021119777A RU2021119777A (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021119777A RU2021119777A (ru) | 2015-05-18 | 2016-05-18 | Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения |
Country Status (21)
Country | Link |
---|---|
US (2) | US10913778B2 (ja) |
EP (2) | EP3298030B1 (ja) |
JP (1) | JP6947642B2 (ja) |
CN (1) | CN108112253B (ja) |
AU (1) | AU2016262845B2 (ja) |
BR (1) | BR112017020445A2 (ja) |
CA (1) | CA2980838A1 (ja) |
DK (1) | DK3298030T3 (ja) |
ES (1) | ES2938525T3 (ja) |
FI (1) | FI3298030T3 (ja) |
HR (1) | HRP20230145T1 (ja) |
HU (1) | HUE061108T2 (ja) |
LT (1) | LT3298030T (ja) |
MX (1) | MX2017014716A (ja) |
PL (1) | PL3298030T3 (ja) |
RS (1) | RS64002B1 (ja) |
RU (2) | RU2754466C2 (ja) |
SG (1) | SG11201707426SA (ja) |
SI (1) | SI3298030T1 (ja) |
WO (1) | WO2016184882A1 (ja) |
ZA (1) | ZA201706061B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
SG11201708339QA (en) * | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
MX2018000447A (es) | 2015-07-15 | 2018-08-15 | Pieris Pharmaceuticals Gmbh | Novedosas proteinas especificas para lag-3. |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
MX2019007795A (es) * | 2017-01-03 | 2019-08-16 | Hoffmann La Roche | Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb. |
JP7267921B2 (ja) | 2017-01-06 | 2023-05-02 | クレシェンド・バイオロジックス・リミテッド | プログラム細胞死(pd-1)に対するシングルドメイン抗体 |
WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
CN110402252A (zh) * | 2017-01-18 | 2019-11-01 | 皮里斯制药有限公司 | 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白 |
AU2018363292A1 (en) * | 2017-11-13 | 2020-05-21 | Crescendo Biologics Limited | Molecules that bind to CD137 and PSMA |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
WO2019185598A1 (en) | 2018-03-26 | 2019-10-03 | 4Sc Ag | Combination comprising hdac inhibitor and cd137 agonist for cancer therapy |
KR20210040103A (ko) * | 2018-07-31 | 2021-04-12 | 피어이스 파마슈티컬즈 게엠베하 | Cd137 및 pd-l1에 특이적인 신규한 융합 단백질 |
CA3124441A1 (en) | 2019-02-26 | 2020-09-03 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
JP7301155B2 (ja) * | 2019-04-12 | 2023-06-30 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | リポカリンムテインを含む二重特異性抗原結合分子 |
CR20210687A (es) * | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
TW202110485A (zh) * | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
WO2024064713A1 (en) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0257956B2 (en) | 1986-08-19 | 2000-11-22 | Genentech, Inc. | Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion |
JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法 |
FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
AU696387B2 (en) | 1994-05-18 | 1998-09-10 | Inhale Therapeutic Systems, Inc. | Methods and compositions for the dry powder formulation of interferons |
DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
AU767131B2 (en) | 1998-06-08 | 2003-10-30 | F. Hoffmann-La Roche Ag | Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C |
US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
AU2001294617A1 (en) | 2000-09-21 | 2002-04-02 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
JP4336771B2 (ja) | 2001-03-09 | 2009-09-30 | モルフォシス アーゲー | 血清アルブミン結合部分 |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
WO2003029471A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
AU2003264100A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
CA2622441A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
JP5608368B2 (ja) | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | 涙リポカリンの突然変異タンパク質およびそれを得るための方法 |
CN101516907B (zh) | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
WO2009012394A1 (en) | 2007-07-17 | 2009-01-22 | Medarex, Inc. | Monoclonal antibodies against glypican-3 |
EP2225268B1 (en) | 2007-10-19 | 2012-08-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
BR112012013662B1 (pt) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico |
DK2606061T3 (da) | 2010-08-16 | 2017-11-06 | Pieris Pharmaceuticals Gmbh | Bindingsproteiner til hepcidin |
NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
RU2015126651A (ru) * | 2012-12-10 | 2017-01-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Способы скрининга |
US20140242077A1 (en) * | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
CN107460201A (zh) * | 2013-05-08 | 2017-12-12 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
IL247715B (en) * | 2014-04-07 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Antigen binding molecules that activate the immune system |
EP3250586B1 (en) | 2015-01-28 | 2021-10-27 | Pieris Pharmaceuticals GmbH | Novel proteins specific for angiogenesis |
TW201636364A (zh) | 2015-02-18 | 2016-10-16 | 賽諾菲公司 | 對於螢光鐵載體及綠膿桿菌螯鐵蛋白具特異性之新穎蛋白 |
SG11201708339QA (en) * | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
CN114316067A (zh) | 2015-05-04 | 2022-04-12 | 皮里斯制药有限公司 | 抗癌融合多肽 |
WO2016184875A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 BR BR112017020445A patent/BR112017020445A2/pt active Search and Examination
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 MX MX2017014716A patent/MX2017014716A/es unknown
- 2016-05-18 DK DK16729794.4T patent/DK3298030T3/da active
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en active Application Filing
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2938525T3 (es) | 2023-04-12 |
ZA201706061B (en) | 2022-05-25 |
EP3298030B1 (en) | 2023-01-18 |
JP2018519803A (ja) | 2018-07-26 |
BR112017020445A2 (pt) | 2018-07-03 |
RU2021119777A (ru) | 2021-08-16 |
CA2980838A1 (en) | 2016-11-24 |
RU2017135539A (ru) | 2019-06-18 |
CN108112253B (zh) | 2022-09-23 |
SG11201707426SA (en) | 2017-10-30 |
EP4219535A1 (en) | 2023-08-02 |
KR20180002855A (ko) | 2018-01-08 |
FI3298030T3 (fi) | 2023-02-22 |
LT3298030T (lt) | 2023-02-27 |
WO2016184882A1 (en) | 2016-11-24 |
US10913778B2 (en) | 2021-02-09 |
CN108112253A (zh) | 2018-06-01 |
RU2754466C2 (ru) | 2021-09-02 |
SI3298030T1 (sl) | 2023-05-31 |
US11919931B2 (en) | 2024-03-05 |
US20210403516A1 (en) | 2021-12-30 |
PL3298030T3 (pl) | 2023-05-08 |
DK3298030T3 (en) | 2023-02-06 |
EP3298030A1 (en) | 2018-03-28 |
JP6947642B2 (ja) | 2021-10-13 |
HRP20230145T1 (hr) | 2023-04-28 |
MX2017014716A (es) | 2018-06-28 |
AU2016262845B2 (en) | 2020-07-23 |
HUE061108T2 (hu) | 2023-05-28 |
AU2016262845A1 (en) | 2018-01-04 |
US20180148485A1 (en) | 2018-05-31 |
RS64002B1 (sr) | 2023-03-31 |